

**GLENMARK PHARMACEUTICALS
EGYPT COMPANY, S.A.E**

**IFRS REPORTING PACKAGE
FOR THE FISCAL YEAR ENDED
MARCH 31, 2020
TOGETHER WITH AUDITOR'S REPORT**

Date: May 14, 2020

To: Walker Chandiook & Co LLP

From: Global View – H S A {Hanna Makanota Fahim – Consultants and Public Accountants}

Re: IFRS Reporting pack of Glenmark Pharmaceuticals Egypt, S.A.E.


Audit Clearance Memorandum

In accordance with the instructions in your letter dated March 2020, we have performed an audit of the IFRS reporting pack of {**Glenmark Pharmaceuticals Egypt, S.A.E.**} a subsidiary of (Glenmark Pharmaceuticals Limited) (“PARENT”), as of March 31, 2020. The Component financials reporting pack has been prepared solely for the purpose of inclusion in the consolidated financial statements of Glenmark Pharmaceuticals Limited (the “Group”).

As stated therein, the Component financial statement has been prepared in accordance with the conformity with International Financial Reporting Standards as issued by International Accounting Standard Board and Group’s accounting policies and the disclosure and presentation requirement of the Group.

The Component financials reporting pack is the responsibility of {**Glenmark Pharmaceuticals Egypt, S.A.E.**} management. Our responsibility is to express an opinion on the Component financial reporting pack based on our audit work.

We conducted our audit work in accordance with the International Standards on Auditing (ISAs). As instructed by you, we planned and performed our audit work to obtain reasonable assurance about whether the Component financial reporting pack contains misstatements that aggregate in excess of component materiality as specified in your instructions. Our audit work included examining, on a test basis, evidence supporting the amounts and disclosures in the Component financial reporting pack. It also included assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of financial information in the specific norms. We believe that our audit work provides a reasonable basis for our opinion.






In our opinion, the Component financials reporting pack of { **Glenmark Pharmaceuticals Egypt, S.A.E.** }, as of March 31, 2020 and for the year then ended, in conformity with International Financial Reporting Standards as issued by International Accounting Standard Board.

This communication is provided to you solely for the information and use of Walker Chandio & Co LLP to assist you in your audit of the consolidated financial statements of the Group and should not be used by anyone for any other purpose.

May 14, 2020

[Global View – H S A – Consultants and Public Accountants]



[Hanna Makanota Fahim – E.R.A.A. 13659]





Glenmark Pharmaceuticals Egypt Co. S.A.E
Statement of Financial Position

	Sch	March-31-2020	March-31-2019
		EGP	EGP
ASSETS		IFRS	IFRS
<i>Current assets</i>			
Cash and cash equivalents	S 1	279,497	558,536
Trade receivables	S 2	19,978,644	15,252,079
Inventories	S 3	7,397,821	6,583,076
Other current financial assets	S 4	1,524,096	1,140,546
Total current assets		29,180,057	23,534,237
<i>Non-current assets</i>			
Property, plant and equipment	S 5	69,254	182,659
Other Intangible Assets	S 6 (A)	667,599	840,094
Right to Use Asset	S 6 (B)	365,853	-
Deferred tax assets (net)		-	-
Total non- current assets		1,102,706	1,022,753
Total assets		30,282,763	24,556,990
LIABILITIES AND STOCKHOLDERS' EQUITY			
<i>Current liabilities</i>			
Trade payables	S 7	5,702,327	479,115
Current tax liabilities		-	-
Short-term borrowings		-	-
Current portion of long term borrowings		-	-
Other liabilities	S 9	3,321,929	4,670,565
Short term financial liabilities	S 10	973,274	317,508
Total current liabilities		9,997,530	5,467,188
<i>Non-current liabilities</i>			
Long-term borrowings	S 11	25,053,124	20,620,448
Other non-current liabilities		-	-
Other non-current financial liabilities	S 12	178,872	-
Total non-current liabilities		25,231,996	20,620,448
Total liabilities		35,229,526	26,087,636
<i>Stockholders' equity</i>			
Equity share capital	S 12	55,426,520	55,426,520
Share premium		-	-
Currency translation reserve		-	-
Retained earnings (losses)	S 12	(60,373,283)	(56,957,166)
		(4,946,763)	(1,530,646)
Non Controlling Interest		-	-
Total stockholders' equity		(4,946,763)	(1,530,646)
Total liabilities and stockholders' equity		30,282,763	24,556,990



(The accompanying notes form an integral part of these financial statements)

(0)





Glenmark Pharmaceuticals Egypt Co. S.A.E

Income Statement	Sch	March-31-2020		March-31-2019	
		EGP		EGP	
		IFRS		IFRS	
Revenues					
Operating revenue		45,478,114		37,155,765	
Other income	S 13	2,153,365		310,267	
Total revenues		47,631,479		37,466,032	
Expenses					
Materials consumed	S 14	17,096,079		13,120,826	
Changes in inventories of finished goods and work-in-process	S 14	444,172		2,016,155	
Purchases of stock-in-trade	S 14	7,035,467		3,657,869	
Employee costs	S 15	10,096,188		8,438,314	
Other expenses	S 16	13,769,787		14,628,979	
Depreciation, amortisation and impairment expense	S5 & S6	487,718		496,144	
Total expenses		48,929,410		42,358,286	
Operating profit / (loss)		(1,297,931)		(4,892,254)	
Finance income		-		-	
Finance costs	S 17	(2,118,185)		(1,823,808)	
Profit/(Loss) before tax		(3,416,117)		(6,716,062)	
Tax expense					
Current tax expenses		-		-	
Deferred tax benefit		-		-	
Total tax expenses		-		-	
Profit/(Loss) for the year		(3,416,117)		(6,716,062)	
Profit (Loss) for the year attributable to:					
Non Controlling Interest		-		-	
Equity shareholders of Glenmark Pharmaceuticals Egypt Co. S.A.E		(3,416,117)		(6,716,062)	



Glenmark Pharmaceuticals Egypt Co. S.A.E

Statement of Comprehensive Income	Sch	March-31-2020	March-31-2019
		EGP	EGP
Profit (Loss) for the year		(3,416,117)	(6,716,061)
Other comprehensive income			
Items that will not be reclassified subsequently to income statement			
- Remeasurement of the net defined benefit plans			
- Income tax relating to the above			
Items that will be reclassified subsequently to income statement			
Exchange differences on translating foreign operations			
Other comprehensive income for the period, net of tax			
Total comprehensive income / (loss) for the period		(3,416,117)	(6,716,061)
Total Comprehensive Income attributable to:			
Non-controlling interest			
Equity shareholders of Glenmark Pharmaceuticals Egypt Co. S.A.E		(3,416,117)	(6,716,061)



Glenmark Pharmaceuticals Egypt Co. S.A.E
STATEMENT OF CASHFLOW

	March-31-2020	March-31-2019
	EGP	EGP
(A) Cash inflow/(outflow) from operating activities		
Profit/(Loss) Before Taxes	(3,416,117)	(6,716,061)
Adjustments to reconcile profit before tax to net cash provided by operating activities:		
Depreciation and amortisation	487,718	496,143
Gain on disposal of property, plant and equipment		
Finance costs		
- Inter company	2,039,797	1,823,808
- Others (Lease)	78,388	
Interest income		
Dividend income		
(Profit)/loss on sale of property, plant and equipments		
Employee benefit obligation		
Provision for doubtful debts / expected credit losses		
Employee share based compensation		
Provision for sales returns		
Unrealised exchange (gain)/loss	(2,151,425)	(264,227)
Operating profit before changes in operating assets and liabilities	(2,961,638)	(4,660,337)
Changes in operating assets and liabilities:		
- Decrease/(increase) in trade receivables	(4,726,565)	(2,977,004)
- Decrease/(Increase) in inventories	(814,744)	(785,192)
- Decrease/(Increase) in other assets	(43,075)	968,577
- Increase/(Decrease) in trade payable and other liabilities		
- Others	3,063,985	1,852,520
- Intercompany	501,110	
Net changes in operating assets and liabilities	(2,019,290)	(941,099)
Income taxes paid		
Net cash generated from operating activities	(4,980,928)	(5,601,436)
(B) Cash inflow/(outflow) from investing activities		
Restricted cash		
Interest received		
Dividend received		
Payments for Purchase of Property, plant and equipment and Intangible assets (including assets under construction)	(15,144)	(3,470)
Proceeds from sale of property, plant and equipment and Intangible assets		
Net cash used in investing activities	(15,144)	(3,470)
(C) Cash inflow/(outflow) from financing activities		
Proceeds from long-term borrowings	4,952,264	
Repayments of long-term borrowings		
Proceeds from / (repayment) of short-term borrowings (net)		
Lease payment	(235,230)	
Proceeds from issue of share capital		
Dividend paid (including tax on dividend)		
Share Application Money		
Net cash generated / (used) from financing activities	4,717,034	-
Effect of exchange rate changes on cash and cash equivalents		
Net increase in cash and cash equivalents	(279,039)	(5,604,906)
Cash and cash equivalents at the beginning of the year	558,536	6,163,442
Cash and cashequivalents at the end of theyear	279,497	558,536
Check	(0)	-



Glenmark
 PHARMACEUTICALS EGYPT





Glenmark Pharmaceuticals Egypt Co. S.A.E
 S 12 - Statement of Changes in Shareholders' Equity
 [All amounts are stated in EGP, unless otherwise stated]

Equity attributable to shareholders of Glenmark Pharmaceuticals Egypt Co. S.A.E								
	Share capital - No. of shares	Share capital	Share premium	Currency Translation reserve	Retained earnings	Total attributable to owners of the parent company	Non- controlling interest	Total stockholders' equity
Balance as at 1 April 2019	55,426,520	55,426,520	-	-	(56,957,166)	(1,530,646)	-	(1,530,646)
Dividends to equity shareholders (including dividend distribution tax)	-	-	-	-	-	-	-	-
Issue of share capital	-	-	-	-	-	-	-	-
Shares issued under Employee Stock Option (ESOP) Scheme	-	-	-	-	-	-	-	-
Employee share based compensation	-	-	-	-	-	-	-	-
Transaction with non controlling interest	-	-	-	-	-	-	-	-
Transactions with owners	55,426,520	55,426,520	-	-	(56,957,166)	(1,530,646)	-	(1,530,646)
Net income for the year	-	-	-	-	(3,416,117)	(3,416,117)	-	(3,416,117)
Other Comprehensive Income:	-	-	-	-	-	-	-	-
Exchange difference on translation of foreign operations	-	-	-	-	-	-	-	-
Remeasurement of the net defined benefit plans (net of tax)	-	-	-	-	-	-	-	-
Total Comprehensive Income	-	-	-	-	-	-	-	-
Balance as at 30 June 2019	55,426,520	55,426,520	-	-	(60,373,283)	(4,946,763)	-	(4,946,763)

[All amounts are stated in EGP, unless otherwise stated]

Equity attributable to shareholders of Glenmark Pharmaceuticals Egypt Co. S.A.E								
	Share capital - No. of shares	Share capital	Share premium	Currency Translation reserve	Retained earnings	Total attributable to owners of the parent company	Non- controlling interest	Total stockholders' equity
Balance as at 1 April 2018	55,426,520	55,426,520	-	-	(50,241,104)	5,185,416	-	5,185,416
Dividends to equity shareholders (including dividend distribution tax)	-	-	-	-	-	-	-	-
Issue of share capital	-	-	-	-	-	-	-	-
Shares issued under Employee Stock Option (ESOP) Scheme	-	-	-	-	-	-	-	-
Employee share based compensation	-	-	-	-	-	-	-	-
Transaction with non controlling interest	-	-	-	-	-	-	-	-
Transactions with owners	55,426,520	55,426,520	-	-	(50,241,104)	5,185,416	-	5,185,416
Net income for the year	-	-	-	-	(6,716,062)	(6,716,062)	-	(6,716,062)
Other Comprehensive Income:	-	-	-	-	-	-	-	-
Exchange difference on translation of foreign operations	-	-	-	-	-	-	-	-
Remeasurement of the net defined benefit plans (net of tax)	-	-	-	-	-	-	-	-
Total Comprehensive Income	-	-	-	-	-	-	-	-
Balance as at 31 March 2019	55,426,520	55,426,520	-	-	(56,957,166)	(1,530,646)	-	(1,530,646)





S 1

Cash and cash equivalents

Cash and cash equivalents include the components as follows:

	EGP	
	March-31-2020	March-31-2019
Cash on hand	14,502	13,994
Cheques in hand		
Cash in current accounts	244,995	464,998
Cash in deposit accounts	20,000	20,000
Cash in current accounts - restricted for use	-	61,392
	-	-
Total	279,497	560,385




S 2

Trade receivables [other receivables can be merged here, if material]

The carrying amount of trade receivables are analysed as follows:

Particulars	EGP	EGP
	March-31-2020	March-31-2019
Gross value	20,122,468	15,252,079
Less: Allowance for credit losses	143,824	-
Net trade receivables	19,978,644	15,252,079




S 3

Inventories

Inventories recognised in the statement of financial position can be analysed as follows:



Particulars	EGP	EGP
	March-31-2020	March-31-2019
Raw materials & Packing Materials	5,456,568	4,197,652
Finished Goods	1,941,252	2,385,424
Total	7,397,821	6,583,076



S 4

Other short term financial assets

Particulars	EGP	EGP
	March-31-2020	March-31-2019
Prepayments and Other current assets	1,524,096.39	1,140,546
Other Receivable		340,475
Total	1,524,096.39	1,481,021



Schedule - 8 I1

Particulars	EGP	
	March 31, 2020	March 31, 2019
	IFRS	IFRS
Loans from Ghannam Pharmaceuticale Limited, India	19,090,852	13,001,376
Interest on Loans	5,962,272	4,812,022
Total	25,053,124	17,813,398

Schedule - 8 I2

Particulars	EGP	
	March 31, 2020	March 31, 2019
	IFRS	IFRS
Lease Liability	178,872	-
Total	178,872	-

Schedule - 8 I

Particulars	EGP	
	March 31, 2020	March 31, 2019
	IFRS	IFRS
Trade payables	5,702,327	479,115
Total	5,702,327	479,115

Schedule - 8 I0

Particulars	EGP	
	March 31, 2020	March 31, 2019
	IFRS	IFRS
Employer Dues	756,465	317,504
Lease Liabilities	216,899	-
Total	973,364	317,504

Schedule - 8 H

Particulars	EGP	
	March 31, 2020	March 31, 2019
	IFRS	IFRS
Continuation of Raw and Packing material		
Opening Stock	4,974,652	1,396,315
Add: Purchases	18,354,995	15,922,173
Less: Closing stock	5,456,598	4,191,632
Consumption of Raw and Packing material	17,896,979	13,126,826
Finished Stock		
Purchases	7,035,467	3,657,856
Opening stock	2,385,424	4,401,579
Closing stock	1,041,252	2,385,424
(Increase)/Decrease in stock of Finished goods	446,172	2,016,143
Total	24,425,717	18,794,849


Schedule - 15

Particulars	EGP	
	March 31, 2020	March 31, 2019
	IFRS	IFRS
Salaries and bonus	9,952,854	7,152,188
Contributions to provident fund and other funds		
Social Insurance company share	694,175	641,530
Recruitment, Training & Education allowance	3,455	36,500
Medical, Life Insurance & Hospitality	145,204	60,000
Staff welfare expenses		
Total	10,795,688	8,415,318

Schedule - 8 I6

Particulars	EGP	
	March 31, 2020	March 31, 2019
	IFRS	IFRS
Sales promotion expenses	3,723,011	3,565,545
Telephone expenses	73,830	157,277
Traveling expenses	824,136	1,025,147
Repairs & Maintenance	6,140	20
Rent	27,464	213,150
Warehouse Rent	266,118	328,608
Electricity charges	23,145	18,554
Contingent	5,396,364	4,751,296
Other operating expenses	2,983,205	3,589,537
Legal Fees	252,320	52,191
Data Services	71,639	-
Allowance for doubtful debts	103,824	-
Total	13,702,787	14,601,343

Handwritten signature and stamp of Ghannam Pharmaceuticale Egypt. The stamp includes the company name in Arabic and English, and the date 15/03/2020.



S 5



Property, plant and equipment

The Group's property, plant and equipment comprise freehold and leasehold land, IT and office equipment, and EGP

	Furniture and fixture	Office Equipment	Total
Cost			
Balance at April 1, 2019	266,771.00	391,327.00	658,098.00
- Acquisitions through business combinations			
- Other acquisitions		15,144.14	15,144.14
- Disposals/Transfers			
- Translation adjustment			
Balance as at March 31, 2020	266,771.00	406,471.14	673,242.14
- Acquisitions through business combinations			
- Other acquisitions			
- Disposals/Transfers			
- Translation adjustment			
Balance as at March 31, 2020	266,771.00	406,471.14	673,242.14
Accumulated Depreciation			
Balance at April 1, 2019	208,994.91	266,483.00	475,477.91
- Depreciation charge for the year	36,914.00	91,596.12	128,510.12
- Impairment loss recognized			
- Disposals/Transfers			
- Translation adjustment			
Balance as at March 31, 2020	245,908.91	358,079.12	603,988.03
- Depreciation charge for the year			
- Impairment loss recognized			
- Disposals/Transfers			
- Translation adjustment			
Balance as at March 31, 2020	245,908.91	358,079.12	603,988.03

Carrying value

At April 1, 2019	57,776.09	124,044.00	182,620.09
At March 31, 2020	20,862.09	48,392.02	69,254.11
At March 31, 2020	20,862.09	48,392.02	69,254.11





Other intangible assets

	EGP	
	Brands	Total
Cost		
Balance at April 1, 2018	2,996,930	2,996,930
- Internally developed	-	-
- Acquired through business combinations	-	-
- Other acquisitions	-	-
- Disposals/ Transfers	-	-
- Translation adjustment	-	-
Balance as at March 31, 2019	2,996,930	2,996,930
- Internally developed	-	-
- Acquired through business combinations	-	-
- Other acquisitions	-	-
- Disposals/ Transfers	-	-
- Translation adjustment	-	-
Balance as at March 31, 2020	2,996,930	2,996,930
Amortisation and impairment		
Balance at April 1, 2018	1,853,717	1,853,717
- Amortisation charge for the year	303,119	303,119
- Impairment loss	-	-
- Amortisation charge for disposals/ transfers	-	-
- Translation adjustment	-	-
Balance as at March 31, 2019	2,156,836	2,156,836
- Amortisation charge for the year	172,495	172,495
- Impairment loss	-	-
- Amortisation charge for disposals/ transfers	-	-
- Translation adjustment	-	-
Balance as at March 31, 2020	2,329,331	2,329,331

Carrying value

At March 31, 2019	840,094	840,094
At March 31, 2020	667,599	667,599
At March 31, 2020	667,599	667,599




S 6 (B)
Right to Use Asset

EGP

	Office Premises	Total
Cost		
Balance at April 1, 2019	-	-
- Internally developed	-	-
- Acquired through business combinations	-	-
- Other acquisitions	552,523	552,523
- Disposals/ Transfers	-	-
- Translation adjustment	-	-
Balance as at March 31, 2020	552,523	552,523
- Internally developed	-	-
- Acquired through business combinations	-	-
- Other acquisitions	-	-
- Disposals/ Transfers	-	-
- Translation adjustment	-	-
Balance as at March 31, 2020	552,523	552,523
Amortisation and impairment		
Balance at April 1, 2019	-	-
- Amortisation charge for the year	186,670	186,670
- Impairment loss	-	-
- Amortisation charge for disposals/ transfers	-	-
- Translation adjustment	-	-
Balance as at March 31, 2020	186,670	186,670
- Amortisation charge for the year	-	-
- Impairment loss	-	-
- Amortisation charge for disposals/ transfers	-	-
- Translation adjustment	-	-
Balance as at March 31, 2020	186,670	186,670

Carrying value

At April 1, 2019	-	-
At March 31, 2020	365,853	365,853
At March 31, 2020	365,853	365,853




S 8

Other liabilities

Other current liabilities are summarized as follows:

	EGP	EGP
	March-31-2020	March-31-2019
Statutory dues	1,967,222	1,328,721
Provisions	1,354,707	3,343,692
Share Capital Advance	-	-
Total	3,321,929	4,672,413





S 13

Other income

Other income is summarised as follows:

	EGP	EGP
	March-31-2020	March-31-2019
Exchange gain (net)	2,151,425	264,227
Miscellaneous income	1,940	46,040
Total	2,153,365	310,267





Schedule S 17

1.2 Finance costs

Finance costs is analysed as follows:

	EGP	EGP
	March-31-2020	March-31-2019
- Interest on loan to Glenmark Pharmaceuticals Ltd	2,039,797	1,823,808
- Interest on Right to Use Asset	78,388	-
Total	2,118,185	1,823,808



Related party transactions

The Group's related parties include its associates and joint venture, key management personnel and others as described below. Unless otherwise stated, none of the transactions incorporate special terms and conditions and no guarantees were given or received. Outstanding balances are usually settled in cash.

1.1 Names of related parties

All related parties and nature of relationship between various related parties are summarized as below

S No.	Nature of the relationship	Related Party's Name
I.	Key Management Personnel (KMP)	
II.	Close family member of KMP with whom the Group has transactions	-
III.	Other Enterprises over which KMP are able to exercise significant influence	-
IV.	Associates	-
V.	Joint Ventures	-

Glenmark Pharmaceuticals Limited, India

1.2 Transactions with KMP, their close family members and enterprises over which they exercise significant influence are as under:


Key management personnel remuneration and amounts of transactions with enterprises over which they exercise significant influence have been summarised below:

	31-Mar-20
Short term employee benefits	
- Salaries including bonuses	
- Social security costs	
- Professional fees	
Total short term employee benefits	
Post employment benefits	
Other long-term benefits	
Termination benefits	
Share based payment expense	
Total benefits	
Total payable	

Key management personnel also participate in post employment benefit plans and other long term benefits provided by the Group. The amounts in respect of these towards the KMP cannot be segregated as these are based on actuarial valuation for all employees of the Group. During the year ended 31 March 2011 and 31 March 2010 no key management personnel has exercised options granted to them.

1.3 Transactions with associates

1.4 Transactions with Related parties	31-Mar-20
Transactions and Closing Balances with related parties-	EGP
(a) the amount of the transactions;	
Investment Made by Glenmark Pharmaceuticals Limited, India during the FY ended 31/3/2017	
Purchases from Glenmark Life Science	112,748
Loan from Glenmark India during the year	4,929,514
Reimbursement of Expenses to Glenmark Kenya	442,145
Interest expenses accrued during the year	2,039,797
(b) the amount of outstanding balances and:	
Payable to Glenmark Pharmaceuticals Limited against purchase made during the year	
Loan and Interest payable to Glenmark Pharmaceuticals Limited	25,053,124
Share Capital Advance	-
Payable to Glenmark Pharmaceuticals Limited Kenya against reimbursement of Expenses made during the year	390,066
Payable to Glenmark Life Science	111,043




Glenmark Pharmaceuticals Egypt

Descriptions	Glenmark India (GPL)		
	Nos of Shares	Document Currency	Local Currency
		USD	EGP
Opening Balance as on April 1st, 2019	55,426,520	7,548,306	55,426,520
Add- Investment made during the Quarter/Period/ Year			
Other Adjustments-			
Realized exchange Gain/(loss)			
Others- Please specify			
Closing Balance as on Mar 31, 2020	55,426,520	7,548,306	55,426,520
Balance as per Confirmation Attached	55,426,520	7,548,306	55,426,520



Difference

OK



Glenmark Pharmaceuticals Egypt

Descriptions	Glenmark India	
	Document Currency	Local Currency
	USD	EGP
Opening Balance as on April 1st, 2019	1,186,072.03	20,620,448
Add- Amount Recd during the Quarter/ Period / Year	300,000.00	4,952,264
Add- Interest Accrued during the year	99,748.80	1,631,834
Less- Payment during the Quarter/ Period/ Year	-	-
- For Principal		
- For Interest		
Other Adjustments-		3.60
Realized exchange (Gain)/loss		
Unrealized exchange (Gain)/loss	(0.40)	(2,151,425.16)
Others- Please specify		
Closing Balance as on Mar 31, 2020	1,585,821.23	25,053,124
Balance as per Confirmation Attached	1,585,821.23	25,053,124
Difference	-	(0.00)





Closing Rate
Average Rate

4.740000
4.320000

EGP

Particulars	Dr	Cr	Type
credit interest	-	-	BS
Other Income (Loss)	-	1,940.00	PL
Glenmark Pharmaceutical Ltd- Capital A/c	-	55,426,520.00	BS
Payable Salary Tax & Withholding Tax & Stamp Tax	-	1,970,651.36	BS
Sales Tax Payable	-	(3,429.31)	BS
Payable Social Insurans	-	549,817.76	BS
Accrued Salaries	-	206,646.96	BS
bank NSGB usd	212,626.11	-	BS
Inventory RM	5,456,568.07	-	BS
Inventory FG	1,941,252.46	-	BS
Local Suppliers	734,743.24	-	BS
Deposits held with others	25,000.00	-	BS
Custody	71,997.00	-	BS
Right to Use Asset	552,523.00	-	BS
Withholding Tax Receivable	692,356.15	-	BS
Capital exp /investment	2,996,929.96	-	BS
AUDI Bank	814.74	-	BS
bank NSGB egp	31,553.82	-	BS
Time Deposit (EGP)	20,000.00	-	BS
Cash on Hand - EGP	898.35	-	BS
Cash on Hand - USD	13,603.57	-	BS
Computers & Note Books	394,973.31	-	BS
Furniture and Equipment	266,769.60	-	BS
Transit Account	-	-	BS
other creditors	-	5,702,327.19	BS
Glenmark India	-	19,090,852.13	BS
Share Capital Advance	-	-	BS
Interest payable on Loan	-	5,962,271.64	BS
Dep Product acquisition	172,538.00	-	PL
Depr Office Furniture exp	36,914.00	-	PL
Depreciation Comp exp	91,596.12	-	PL
Acc dep Office Furniture	-	245,908.87	BS
Acc dep Procutt acquisition	-	2,329,331.27	BS
Acc Depreciation Comp exp	-	346,579.93	BS
Rent Expense	27,864.13	-	PL
Warehouse rent	266,118.18	-	PL
Telephone Expense	73,829.62	-	PL
Office Supplies	32,892.60	-	PL
Repairs and Maintenance	6,140.00	-	PL
Shipping Exp.	647,341.15	-	PL
misc expenses	222,845.26	-	PL
Loss on sale of fixed assets	-	-	PL
Courier expenses	9,705.67	-	PL
Professional Fees	300,654.00	-	PL
Bank Service Charges	8,620.89	-	PL
Electricity & Water	25,155.26	-	PL
Employees Severance	111,587.78	-	PL
Dues and Subscriptions	633,064.90	-	PL
Forex(Gain/Loss)	-	2,151,425.16	PL
Impairment Loss AR	-	-	PL
Impairment Loss Advance Payment	-	-	PL
Computer and Internet Expenses	100,853.00	-	PL

Travel Accommodation	800,375.99	-	PL
Travel & Transp Expense Admin	-	-	PL
Travel & Transp Expense Field Force	-	-	PL
Foreign Travel Expense	-	-	PL
Social insurance- company share	694,175.34	-	PL
Payroll Expenses	7,332,677.90	-	PL
Bonus	1,608,588.00	-	PL
recruitment fees	-	-	PL
Education allowance	-	-	PL
Registration expenses	743,743.87	-	PL
Audit fees	-	-	PL
Training exp for medical reps	3,455.00	-	PL
Subscription	-	-	PL
Interest on Loan	2,039,797.43	-	PL
Automobile Expense	252,319.96	-	PL
Brokerage fees	-	-	PL
Unrealized foreign exchane loss	-	-	PL
Cash discount	-	-	PL
Inventory fees	-	-	PL
Hospitality exp	77,101.99	-	PL
Cleaning Services	46,217.50	-	PL
Advertising and Promotion	-	-	PL
FOC	2,212,618.94	-	PL
Expired	56,840.00	-	PL
Machinery Amortization	-	-	PL
Marketing Activities	361,135.38	-	PL
Amortisation-Right to Use Asset	186,670.00	-	PL
Data Services	71,639.00	-	PL
Interest on Right to Use Asset	78,388.00	-	PL
Allowance for doubtful debts	143,824.00	-	PL
Marketing Advertising & Publica	1,710.00	-	PL
Marketing Conference	737,532.19	-	PL
Medical Records and Supplies	201,816.37	-	PL
Marketing National & Int'l Con.	-	-	PL
Marketing Incentives	-	-	PL
Marketing New Prod Intro	-	-	PL
Marketing Sales & Promotion Art	151,358.46	-	PL
Marketing Sales Prom. Litera	-	-	PL
Medical insurance	268,601.82	-	PL
Allowance for doubtful debts.	-	143,824.00	BS
Lease	-	395,681.00	BS
Provi. Amort- Right to Use aset	-	186,670.00	BS
Provisions	-	1,354,707.14	BS
Provision expenses	237,266.22	-	PL
Deferred Tax Income	-	-	PL
COGS	24,575,717.30	-	PL
Sales Revenue	-	45,478,113.59	PL
Commission On Sales	5,396,304.40	-	PL
Accounts Receivable	20,122,467.94	-	BS
Retained Losses	56,957,165.75	-	BS
Products acquisition	-	-	BS
Grand Total	141,539,838.69	141,539,838.69	BS



رئيس مجلس الإدارة
التوقيع: [Signature]

Glenmark Pharmaceuticals Egypt Company, S.A.E.**Notes to IFRS reporting package
For the financial year ended March 31, 2020****1. Background on the company and purpose**

Glenmark Pharmaceuticals Egypt Company, S.A.E. was established on November 6, 2008 as a joint Stock Company in Egypt under the provisions of Companies' Law no. 159 for year 1981 and Law no. 95 for year 1992 and their executive regulations.

The company was registered under number 35429 in the commercial register on November 6, 2008.

The purpose of the company is trading in medical and pharmaceutical products of all types (purchasing, selling, and exporting), obtaining, acquiring, utilizing, and selling patents, invention certificates, licences, inventions, and developments relevant to technical procedures, trademarks, commercial names relating to intellectual rights whether on its own or through others.

a. Statement of compliance

This reporting package has been prepared in accordance with the recognition and measurement criteria of International Financial Reporting Standards, applicable requirements of the Egyptian Law and the disclosure and presentation requirements of the Group.

b. Basis of preparation

The reporting package has been prepared on the historical cost basis and the going concern basis. Except for certain financial instruments, are measured at revalued amounts or fair values at the end of each reporting period. Historical cost is generally based on the fair value of the consideration given in exchange for goods or services.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value measurement is based on the presumption that the transaction to sell the asset or transfer the

liability takes place either in the principal market for the asset or liability, or in the absence of a principal market, in the most advantageous market for the asset or liability.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest. A fair value measurement of a non-financial asset takes into account a market participant's ability to generate economic benefits by using the asset in its highest and best use or by selling it to another market participant that would use the asset in its highest and best use.

Fair value

Fair value of financial instruments hierarchy levels 1 to 3 are based on the degree to which the fair value is observable:

- Level 1 fair value measurements are those derived from quoted prices in active markets for identical assets or liabilities
- Level 2 fair value measurements are those derived from inputs other than quoted prices included in level 1 that are observable for the asset or liability either directly or indirectly.
- Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data.

2. Significant accounting policies

The principal accounting policies are set out below.

a. Revenue recognition

Revenue from the sale of goods is measured at the fair value of the consideration received or receivable and is reduced for estimated customers' returns; value added tax and applicable trade discounts and allowances.

Revenues from the sale of goods is recognized when the goods are delivered and titles have passed, at which time all the following conditions are satisfied:

- The amount of revenue can be measured reliably.
- It is probable that the economic benefits associated with the transactions will flow to the company, and

- The cost incurred or to be incurred in respect of the transactions can be measured reliably.
- The company has transferred to the buyer the significant risks and rewards of ownership the goods.

b. Leasing – Company as a lessee

The Company makes an assessment on the expected lease term on a lease-by-lease basis and thereby assesses whether it is reasonably certain that any options to extend or terminate the contract will be exercised. In evaluating the lease term, the Company considers factors such as any significant leasehold improvements undertaken over the lease term, costs relating to the termination of the lease and the importance of the underlying asset to operations taking into account the location of the underlying asset and the availability of suitable alternatives. The lease term in future periods is reassessed to ensure that the lease term reflects the current economic circumstances.

The company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the company assesses whether: (1) the contract involves the use of an identified asset (2) the company has substantially all of the economic benefits from use of the asset through the period of the lease and (3) the company has the right to direct the use of the asset.

At the date of commencement of the lease, the company recognizes a right-of-use asset ("ROU") and a corresponding lease liability for all lease arrangements in which it is a lessee, except for leases with a term of twelve months or less (short-term leases) and low value leases. For these short-term and low value leases, the company recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease.

The right-of-use assets are initially recognized at cost, which excludes the initial amount of the lease liability adjusted for any lease payments made at or prior to the commencement date of the lease plus any initial direct costs less any lease incentives due to practical expedient. They are subsequently measured at cost less accumulated depreciation and impairment losses.

Right-of-use assets are depreciated from the commencement date on a straight-line basis over the shorter of the lease term and useful life of the underlying asset. Right of use assets

are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable.

The lease liability is initially measured at amortized cost at the present value of the future lease payments. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, using the incremental borrowing rates in the country of domicile of the leases. Lease liabilities are re-measured with a corresponding adjustment to the related right of use asset if the company changes its assessment if whether it will exercise an extension or a termination option.

Lease liability and ROU asset have been separately presented in the Balance Sheet and lease payments have been classified as financing cash flows.

c. Foreign currencies

The functional and reporting currency of the company is the Egyptian pound. Foreign currency transactions are recognized into the functional currency using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognized in profit or loss in the period in which they arise.

Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

d. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax. Income tax is calculated in accordance with the Egyptian Tax Law.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from "profit before tax" as reported in the company's statement of profit and loss because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible.

The current tax is calculated using tax rates that have been enacted or substantively enacted at the end of the reporting period.

Deferred tax

Deferred tax is recognized on temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit.

Deferred tax liabilities are generally recognized for all taxable temporary differences, and deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realized, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period.

The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

A deferred tax asset is recognized for the unused tax losses carried forward only to the extent that the company has sufficient taxable temporary differences against which unused tax losses can be utilized.

e. Property, plant and equipment

Items of property, plant and equipment are stated in the statement of financial position at the acquisition cost less accumulated depreciation and any recognized impairment loss. Items of property, plant and equipment are depreciated using the straight line method.

Depreciation is recognized in income statement on a straight-line basis over the estimated useful lives of property, plant and equipment. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

The estimated useful lives for each class of fixed assets are illustrated below:

Asset category	Estimated useful life
Computers and software	3 years
Office furniture	3 years

f. Intangible assets

Intangible assets are purchased products' licenses that are carried at cost less accumulated amortization and any recognized accumulated impairment losses. Subsequent expenditure is capitalized only when it increases the future economic benefits embodied in the specific asset to which they relate. They are amortized over their estimated life which is the period since its acquisition date (date of approval of the Ministry of Health to transfer title of the product to Glenmark Egypt) to invalidation date (i.e. 10 years from registering the product at the Ministry of Health).

Acquisition took place after registering the products within a period of 0 to 2.7 years at Ministry of Health, thus amortization period varies from (7.3 to 10 years). Amortization starts in the month following the acquisition date using the straight-line method.

The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis.

g. Inventories

Inventories are stated at the lower of cost and net realizable value. Net realizable value represents the estimated selling price for inventories less all estimated costs of completion and costs necessary to make the sale. Costs of inventories are determined on the following basis:

- a) Raw materials: at the lower of cost using the weighted average method or net realizable value.
- b) Finished products: at the lower of the cost of production of each batch based on the costing sheets or net realizable value.
- c) Work in process: at the lower of the cost of production of the latest completed phase based on the costing sheets or net realizable value.

h. Impairment of assets

At the end of each reporting period, the company reviews the carrying amounts of its tangible and intangible assets, to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). If the recoverable amount of the asset is estimated to be lower than its carrying amount, then the carrying amount of the asset is reduced to its estimated recoverable amount, and an impairment loss is recognized immediately in profit or loss. Recoverable amount is the higher of fair value less costs of disposal and value in use.

If an impairment loss subsequently reverses, the carrying amount of the asset is increased to the revised estimate of its recoverable amount but not in excess of the amount that would have been determined had no impairment loss been recognized for the asset (group of related assets) in prior years. A reversal of an impairment loss is recognized immediately in profit or loss.

i. Provisions

Provisions are recognized when the company has a present obligation (legal or constructive) as a result of a past event, it is probable that the company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows, when the effect of the time value of money is material. All provisions are reviewed at each reporting date and adjusted to reflect the current best estimate.

j. Financial instruments

Financial assets and financial liabilities are recognized when the company becomes a party to the contractual provisions of the instruments. Financial assets and financial liabilities are initially measured at fair value. Financial assets are derecognized when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and all substantial risks and rewards are transferred. A financial liability is derecognized when it is extinguished, discharged, cancelled or expires.

Financial assets are represented in cash and bank balances, trade and other receivables and other debit balances. Financial liabilities are represented mainly in trade payables, other credit balances and borrowings. Borrowings are initially measured at fair value and subsequently measured at amortized cost using effective interest rate method. Trade payables are recognized initially at their transaction values which also approximate their fair values and subsequently measured at amortized cost less settlement payments.

Impairment testing of financial assets

A financial asset is assessed at each reporting date to determine whether there is any objective evidence that it is impaired. A financial asset is considered to be impaired if objective evidence indicates that one or more events had a negative effect on the estimated future cash flows of that asset.

An impairment loss, in respect of a financial asset measured at amortized cost is calculated as the difference between its carrying amount, and the present value of the estimated future cash flows discounted at the original effective interest rate. An impairment loss, in respect of an available-for-sale financial asset is calculated by reference to its fair value.

Significant financial assets are tested for impairment on an individual basis. All impairment losses are recognized in income statement.

k. De-recognition of financial assets and financial liabilities

The company derecognizes a financial asset only when the contractual rights to the cash flows from the asset expire; or it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. On de-recognition of a financial asset in its entirety, the difference between the asset's carrying amount and the sum of consideration received or receivable is recognized in profit or loss.

The company derecognizes a financial liability when, and only when, the company's obligations are discharged, cancelled, or expired. The difference between the carrying amount of the financial liability derecognized and the consideration paid or payable is recognized in profit or loss.

l. Borrowing Costs

Borrowing costs primarily comprise interest on the Group's borrowings. Borrowing costs directly attributable to the acquisition, construction or production of a qualifying asset are capitalized during the period of time that is necessary to complete and prepare the asset for its intended use or sale. Other borrowing costs are expensed in the period in which they are